Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
icosabutate (2 trials)
nst-1024 (2 trials)
omega-3 fatty acids (Omacor) (2 trials)
moxifloxacin (avelox) (1 trial)
Dyslipidemias (Phase 1)
Fatty Liver (Phase 2)
Hypertriglyceridemia (Phase 1)
Non-alcoholic Fatty Liver Disease (Phase 2)
Trials (6 total)
Trial APIs (4 total)